Genentech’s New AMD Contender, Takeda’s Win Against CMV, and the IPOs Continue

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Mental Health: A New Frontier for Biotech
J&J Vaccine OK’d, Morphic Nails Integrin Target, & AZ Grabs $1B for Moderna Shares
Pfizer/BioNTech Ace Real-World Test, J&J Faces FDA Scrutiny, & Merck Pays Up
Alta Reloads, AstraZeneca Loses Cancer Indication, & Sanofi/GSK Vaccine Reboots